PetVivo Holdings to File Quarterly Report on November 13

MINNEAPOLIS, Nov. 11, 2026 /CourierPR/ -- PetVivo Holdings, Inc. (OTCQB: PETV) is set to file its Quarterly Report on Form 10-Q for the fiscal second quarter ended September 30, 2026, on November 13, 2026. The company, which focuses on the commercialization of innovative medical devices and therapeutics for equine and companion animals, announced this change in its communication strategy.

Beginning with this filing, PetVivo will communicate its quarterly financial results and related disclosures through its SEC filings. The company does not intend to issue separate quarterly results press releases or conduct quarterly earnings conference calls. This move is part of PetVivo's ongoing efforts to streamline its communication processes and adapt to its evolving business and investor base.

According to the release, the company's commitment to keeping shareholders informed and maintaining an open dialogue remains unchanged. PetVivo encourages shareholders to review its reports through the SEC’s EDGAR database. The company also stated that it will revisit this approach as its business and investor base evolve and currently anticipates resuming quarterly earnings releases and conference calls in connection with any future uplisting to a national securities exchange. Any such uplisting would be subject to applicable listing requirements and approvals.

PetVivo Holdings, Inc. is an emerging biomedical device company focused on the development, manufacturing, commercialization, and licensing of innovative medical devices, biomaterials, and therapeutics for animal and human health. The company's lead product, SPRYNG® with OsteoCushion® technology, is a veterinarian-administered, intra-articular injection for the management of lameness and other joint-related afflictions, including osteoarthritis, in cats, dogs, and horses. This product is currently available for commercial sale.

The company's strategy is to leverage its proprietary technologies, intellectual property, and scientific expertise to develop and commercialize products addressing unmet needs across veterinary and human medicine. PetVivo has a robust pipeline of products for the treatment of animals and people, with a portfolio of twelve issued and pending patents and six trade secrets protecting its biomaterials, products, production processes, and methods of use.